12-09-2022 | Primary care | News
Formal recognition of type 2 diabetes remission in primary care may lead to suboptimal health monitoring, a study suggests.
10-17-2022 | Healthcare costs | News
Findings from a nationally representative US survey show that a substantial minority of people with diabetes ration their use of insulin because of issues with affordability.
10-04-2022 | Healthcare costs | News
The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.
09-13-2022 | Risk factors | News
Researchers find that a single questionnaire item assessing vitality predicts major adverse cardiovascular events in people with type 2 diabetes.
08-22-2022 | COVID-19 | News
Findings from the phase 2 ARCADIA trial suggest that treatment with a glucokinase activator may aid the recovery of people with diabetes who are hospitalized with severe COVID-19.
08-15-2022 | Comorbidities | News
Clinical complexity and treatment burden have both increased over recent years among people with diabetes in the USA, say researchers.
05-31-2022 | COVID-19 | News
The disruption of routine diabetes care during the pandemic may have resulted in an increased risk for mortality from causes not linked to COVID-19, research suggests.
04-01-2022 | DUKPC 2022 | Conference coverage | News
The proven cardiovascular benefits of SGLT2 inhibitors has not led doctors to prioritize their use in people at high risk, show findings from UK general practice.